VOR

Vor Biopharma Inc.

Healthcare
Biotechnology
$1.21B market cap

Forecast run · Sep 14, 2026Upside rank 443 of 3,136

Model Signal

ForecastQ Daily Probabilities

57.0%

31.8%

33.8%

Analyst Consensus

Recommendation2.23/5 Buy

Last price$22.30

Price target$29.00

Implied move+30.0%

Analysts13

ForecastQ Portfolios

VOR is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.